Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
about
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
P2860
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
@en
type
label
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
@en
prefLabel
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
@en
P2860
P1476
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.
@en
P2093
Masafumi Taniwaki
Tsutomu Kobayashi
P2860
P304
P356
10.1586/14737140.2015.1044249
P50
P577
2015-05-06T00:00:00Z